HSBC Adjusts Price Target on Labcorp Holdings to $330 From $270

The FDA cleared a new blood test, Elecsys pTau217, developed by Roche and Eli Lilly, for evaluating Alzheimer's disease in people 55+. The test measures phosphorylated tau 217, a biomarker linked to amyloid pathology. It is designed to support diagnostic assessments but not replace full medical evaluations. Roche and Lilly aim to make the test accessible in primary care settings, potentially improving early diagnosis and treatment planning.

Piper Sandler raised Labcorp's price target to $309 from $300 but kept a 'Neutral' rating. The average target is $342.94, suggesting 1.6% upside, while the highest target is $385, implying 14%.

Labcorp (NYSE: LH) announced it will offer the Elecsys® pTau-217 blood test, the first FDA-cleared single-biomarker test to detect Alzheimer's disease pathology. Developed by Roche Diagnostics, the test measures phosphorylated Tau 217, an indicator of amyloid pathology, in individuals 55 and older with cognitive decline symptoms. The test will be available nationwide in primary and specialty care settings, providing a standardized approach to patient assessment. Labcorp plans to make the test av

Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.

Labcorp said the FDA approved its PGDx Elio Tissue Complete CDx companion diagnostic, which uses next-generation sequencing to detect BRAF V600E and V600K variants in tumor tissue for advanced melanoma. The test is intended to identify patients eligible for FDA-approved BRAF inhibitors or BRAF/MEK combination therapies, supporting treatment selection.

Labcorp said the FDA approved its PGDx Elio Tissue Complete CDx companion diagnostic, which uses next-generation sequencing to detect BRAF V600E and V600K variants in tumor tissue for patients with advanced melanoma. The test is intended to identify eligibility for FDA-approved BRAF inhibitors or BRAF/MEK combination therapies, supporting treatment selection and molecular profiling in oncology care.